Novartis (SWX:NOVN) Says AI Could Speed Drug Discovery And Development

• Novartis CEO has outlined plans to scale the use of artificial intelligence across the company’s research and development operations.
• The focus is on using AI to shorten drug discovery timelines and support better clinical decision making.
• This shift points to a potential long term change in how Novartis approaches its core business of developing new medicines.

For investors watching SWX:NOVN, the update on AI comes after a period of strong share price performance, with the stock at CHF125.34 and up 38.7% over the past year and 89.4% over five years. Returns of 15.5% year to date put Novartis ahead of many large pharmaceutical peers, which helps explain why any change in its research model attracts close attention.

The CEO’s comments on AI suggest management is aiming to reshape how Novartis sources and tests future drug candidates, rather than focusing only on near term product news. For long term holders, the key question is how effectively this technology push can translate into a broader pipeline and potentially support clinical success over time.

Stay updated on the most important news stories for Novartis by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novartis.

We've flagged 1 risk for Novartis. See which could impact your investment.

For Novartis, the CEO’s focus on AI in drug discovery sits alongside very concrete product progress, such as the recent traditional US approval for Fabhalta in IgA nephropathy. The AI push is about trying to generate more candidates like Fabhalta faster, by improving target selection, molecule design and trial execution. That matters in a market where peers such as Pfizer, Bristol Myers Squibb and Roche are also investing in AI-powered tools to sharpen their pipelines. At the same time, Novartis has reported higher intangible asset impairments of US$199 million in the latest quarter and net income of US$3,264 million on US$14,408 million of sales, which underlines that not every R&D decision pays off. For you as an investor, the AI message is less about near term earnings and more about whether Novartis can shift its product mix toward more high-value therapies over time.

How This Fits Into The Novartis Narrative

• The AI build out supports the existing narrative that a broad, data rich pipeline and productivity gains in R&D can help Novartis pursue growth while seeking better margins from complex therapies.
• Higher R&D intensity, reflected in rising impairment charges, could challenge the idea that operational efficiency alone will drive margin expansion if AI projects do not translate into enough successful launches.
• The CEO’s comments on AI driven trial success probabilities are not explicitly captured in the narrative, which mainly emphasizes product approvals and advanced therapies rather than the tools used to generate them.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Novartis to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ AI projects can be costly and may lead to further impairment charges if drug candidates do not progress, which could weigh on reported profitability.
• ⚠️ Competition from other large pharmaceuticals working on AI enabled R&D, including Bristol Myers Squibb and others, may limit any edge Novartis can gain from these tools.
• 🎁 The combination of AI driven discovery and recent approvals like Fabhalta offers scope for a broader kidney and immunology franchise, which could support revenue breadth over time.
• 🎁 If AI shortens development timelines, Novartis could bring more late stage assets to regulators sooner, which may help offset revenue pressure from loss of exclusivity and pricing headwinds.

What To Watch Going Forward

From here, it is worth watching how often Novartis links specific future approvals or late stage trial readouts directly to its AI platforms, and whether impairment charges stay contained as these tools scale. Monitoring commentary on R&D productivity on upcoming earnings calls, alongside updates on products such as Fabhalta and other rare disease assets, can help you judge whether the AI push is feeding into the pipeline or primarily increasing spend.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Novartis, head to the community page for Novartis to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com